Becton, Dickinson and Company (BDX) Stock Forecast
Data as of Jun 17, 2026Healthcare · Current price $145.00 (-0.39%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 17, 2026 | Jason Bednar | Piper Sandler | $159.00 | +9.7% |
| Apr 10, 2026 | David Roman | Goldman Sachs | $167.00 | +15.2% |
| Feb 10, 2026 | Shagun Singh | RBC Capital | $172.00 | +18.6% |
| Feb 10, 2026 | Matt Miksic | Barclays | $202.00 | +39.3% |
| Jan 28, 2026 | Jason Bednar | Piper Sandler | $161.16 | +11.2% |
| Dec 2, 2025 | Patrick Wood | Morgan Stanley | $165.09 | +13.9% |
| Apr 23, 2025 | Jason Bednar | Piper Sandler | $204.40 | +41.0% |
| Oct 1, 2024 | Vijay Kumar | Evercore ISI | $227.99 | +57.2% |
| Oct 1, 2024 | Joanna Wuensch | Citigroup | $216.19 | +49.1% |
| Aug 2, 2024 | Jayson Bedford | Raymond James | $212.26 | +46.4% |
| Aug 2, 2024 | Larry Biegelsen | Wells Fargo | $220.13 | +51.8% |
| Jul 2, 2024 | Becton Dickinson | Evercore ISI | $224.06 | +54.5% |
| May 30, 2024 | David Roman | Goldman Sachs | $215.41 | +48.6% |
| May 6, 2024 | Matt Miksic | Barclays | $245.28 | +69.2% |
| Apr 8, 2024 | David Toung | Argus Research | $235.85 | +62.7% |
| Jun 25, 2022 | Larry Biegelsen | Wells Fargo | $231.92 | +59.9% |
| Mar 3, 2022 | Travis Steed | Bank of America Securities | $227.99 | +57.2% |
| Feb 3, 2022 | Jason Bednar | Piper Sandler | $208.33 | +43.7% |
Top Analysts Covering BDX
BDX vs Sector & Market
| Metric | BDX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.62 | 2.24 | 2.40 |
| Analyst Count | 16 | 8 | 19 |
| Target Upside | +19.1% | +11475.0% | +17.1% |
| P/E Ratio | 36.71 | 3.88 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $4.89B | $4.90B | $4.92B | 7 |
| 2026-09-30 | $5.05B | $5.09B | $5.12B | 4 |
| 2026-12-31 | $4.57B | $4.61B | $4.64B | 4 |
| 2027-03-31 | $4.75B | $4.79B | $4.82B | 4 |
| 2027-06-30 | $5.00B | $5.04B | $5.08B | 3 |
| 2027-09-30 | $5.22B | $5.27B | $5.30B | 3 |
| 2028-09-30 | $20.33B | $20.37B | $20.42B | 7 |
| 2029-09-30 | $21.01B | $21.12B | $21.32B | 3 |
| 2030-09-30 | $21.78B | $21.90B | $22.10B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $3.03 | $3.08 | $3.17 | 9 |
| 2026-09-30 | $4.11 | $4.16 | $4.19 | 3 |
| 2026-12-31 | $2.79 | $2.82 | $2.84 | 7 |
| 2027-03-31 | $3.03 | $3.06 | $3.09 | 3 |
| 2027-06-30 | $3.39 | $3.43 | $3.46 | 3 |
| 2027-09-30 | $4.05 | $4.10 | $4.13 | 4 |
| 2028-09-30 | $14.18 | $14.28 | $14.45 | 1 |
| 2029-09-30 | $15.12 | $15.22 | $15.41 | 1 |
| 2030-09-30 | $16.41 | $16.53 | $16.73 | 1 |
Frequently Asked Questions
What is the analyst consensus for BDX?
The consensus among 16 analysts covering Becton, Dickinson and Company (BDX) is Hold with an average price target of $193.80.
What is the highest price target for BDX?
The highest price target for BDX is $245.28, set by Matt Miksic at Barclays on 2024-05-06.
What is the lowest price target for BDX?
The lowest price target for BDX is $159.00, set by Jason Bednar at Piper Sandler on 2026-04-17.
How many analysts cover BDX?
16 analysts have issued ratings for Becton, Dickinson and Company in the past 12 months.
Is BDX a buy or sell right now?
Based on 16 analyst ratings, BDX has a consensus rating of Hold (2.62/5) with a +19.1% upside to the consensus target of $193.80.
What are the earnings estimates for BDX?
Analysts estimate BDX will report EPS of $3.08 for the period ending 2026-06-30, with revenue estimated at $4.90B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.